Able Wealth Management »

Brainstorm Cell Therapeutics shares owned by Able Wealth Management

Quarter-by-quarter ownership of Brainstorm Cell Therapeutics (BCLI) shares owned by Able Wealth Management from 13F filings

Historical chart of Able Wealth Management investment in Brainstorm Cell Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Brainstorm Cell Therapeutics held by Able Wealth Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Brainstorm Cell Therapeutics by Able Wealth Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $523 1.9k 0.27

More positions owned by Able Wealth Management

iShares Short Treasury Bond ETF Etf (SHV)
iShares MSCI ACWI ETF Etf (ACWI)
iShares Core S&P 500 ETF Etf (IVV)
iShares Edge MSCI Min Vol USA ETF Etf (USMV)
iShares Core S&P U.S. Value ETF Etf (IUSV)
Fidelity Enhanced Large Cap Core Etf Stock (FELC)
iShares Core S&P U.S. Growth ETF Etf (IUSG)
JPMorgan U.S. Quality Factor ETF Etf (JQUA)
Invesco S&P 100 Equal Weight ETF Etf (EQWL)
iShares Russell 1000 Growth ETF Etf (IWF)
iShares Core S&P Total U.S. Stock Market ETF Etf (ITOT)
Apple Stock (AAPL)
iShares S&P 500 Value ETF Etf (IVE)
Mastercard Incorporated Stock (MA)
Pacer US Cash Cows 100 ETF Etf (COWZ)

View all positions for Able Wealth Management

Top funds holding Brainstorm Cell Therapeutics

Vanguard Group
Liberty Wealth Management
Weaver Consulting Group
Caldwell Sutter Capital
Abner, Herrman & BrocK
Raymond James & Associates
ADAR1 Capital Management
Ikarian Capital
Kingswood Wealth Advisors
Citadel Advisors
Virtu Financial
Jmac Enterprises
Barclays
Wells Fargo & Company
Saxony Capital Management

View all funds holding Brainstorm Cell Therapeutics